2018 Coronary Artery Disease Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Coronary Artery Disease Market

2018 Coronary Artery Disease Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Coronary Artery Disease Market

  • June 2018 •
  • 70 pages •
  • Report ID: 5442346 •
  • Format: PDF
Coronary artery disease is a heart condition in which plaque piles up in arteries of a patient, which reduces the area for free flow of blood, thereby, causing angina or chest pain. This can eventually turn out to be a heart attack and arrhythmia. With an estimated 18 million population being affected in the US, Coronary artery diseases are among the most rapidly expanding disease in the US and world. Further, the US Coronary Heart disease market is sized at $95 billion during 2017.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Coronary Artery Disease pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Coronary Artery Disease pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Coronary Artery Disease pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.